The HEAL Initiative is offering this grant for multisite pragmatic or implementation trials aimed at improving sickle cell disease (SCD) pain management. This grant is for assessing “real-world” uptake of pharmacologic, nonpharmacologic, or multicomponent approaches within healthcare systems. Trials may address social barriers like stigma. While opioids can be included, they should not be the sole intervention. The overall goal is to enhance guideline adherence and improve SCD pain outcomes. Studies must be embedded in three or more healthcare systems, primarily using electronic records, collaborating with coordinating centers.
Opportunity ID: 336369
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AT-22-004 |
| Funding Opportunity Title: | HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.213 — Research and Training in Complementary and Integrative Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 29, 2021 |
| Last Updated Date: | Oct 29, 2021 |
| Original Closing Date for Applications: | Dec 15, 2021 |
| Current Closing Date for Applications: | Dec 15, 2021 |
| Archive Date: | Jan 20, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses State governments City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) County governments For profit organizations other than small businesses Independent school districts Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials supported under this initiative could also address social and structural barriers such as stigma and racial bias to SCD pain management care. The overall goal of this initiative is to support the “real world” assessment of pain management interventions and/or health care strategies to enhance adherence to pain management guidelines in health care systems that may lead to improved SCD pain management, allowing access to opioid pain management when needed. This FOA requires that the intervention under study be embedded into health care delivery system, real world settings, and it is expected that most data will be obtained through the electronic records of the health care system. Trials should be conducted across three or more health care systems (HCS) that provide care to SCD patient populations. Clinical trials will be conducted within the infrastructure of the HEAL Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) Program Coordinating Center, which has dedicated pain, implementation science, and pragmatic clinical trial design. Awarded applicants will work with the Health Care Systems Research Collaboratory Coordinating Center (HCS CCC) (https://rethinkingclinicaltrials.org/) to facilitate further planning and refinement of the proposed study in partnerships with health care delivery systems. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AT-22-004.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00269916 | Nov 15, 2021 | Dec 15, 2021 | View | |
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270466 | Nov 18, 2021 | Dec 15, 2021 | View |
Package 1
Mandatory forms
336369 RR_SF424_2_0-2.0.pdf
336369 PHS398_CoverPageSupplement_5_0-5.0.pdf
336369 RR_OtherProjectInfo_1_4-1.4.pdf
336369 PerformanceSite_2_0-2.0.pdf
336369 RR_KeyPersonExpanded_2_0-2.0.pdf
336369 RR_Budget_1_4-1.4.pdf
336369 PHS398_ResearchPlan_4_0-4.0.pdf
336369 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
336369 RR_SubawardBudget30_1_4-1.4.pdf
336369 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
336369 RR_SF424_5_0-5.0.pdf
336369 PHS398_CoverPageSupplement_5_0-5.0.pdf
336369 RR_OtherProjectInfo_1_4-1.4.pdf
336369 PerformanceSite_4_0-4.0.pdf
336369 RR_KeyPersonExpanded_4_0-4.0.pdf
336369 RR_Budget_3_0-3.0.pdf
336369 PHS398_ResearchPlan_4_0-4.0.pdf
336369 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
336369 RR_SubawardBudget30_3_0-3.0.pdf
336369 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
